Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.

Lieberman NAP, DeGolier K, Kovar HM, Davis A, Hoglund V, Stevens J, Winter C, Deutsch G, Furlan SN, Vitanza NA, Leary SES, Crane CA.

Neuro Oncol. 2019 Jan 1;21(1):83-94. doi: 10.1093/neuonc/noy145.

PMID:
30169876
2.

Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers.

Tsafou K, Katschnig AM, Radic-Sarikas B, Mutz CN, Iljin K, Schwentner R, Kauer MO, Mühlbacher K, Aryee DNT, Westergaard D, Haapa-Paananen S, Fey V, Superti-Furga G, Toretsky J, Brunak S, Kovar H.

Oncotarget. 2018 Jul 24;9(57):31018-31031. doi: 10.18632/oncotarget.25760. eCollection 2018 Jul 24.

3.

Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility.

Machiela MJ, Grünewald TGP, Surdez D, Reynaud S, Mirabeau O, Karlins E, Rubio RA, Zaidi S, Grossetete-Lalami S, Ballet S, Lapouble E, Laurence V, Michon J, Pierron G, Kovar H, Gaspar N, Kontny U, González-Neira A, Picci P, Alonso J, Patino-Garcia A, Corradini N, Bérard PM, Freedman ND, Rothman N, Dagnall CL, Burdett L, Jones K, Manning M, Wyatt K, Zhou W, Yeager M, Cox DG, Hoover RN, Khan J, Armstrong GT, Leisenring WM, Bhatia S, Robison LL, Kulozik AE, Kriebel J, Meitinger T, Metzler M, Hartmann W, Strauch K, Kirchner T, Dirksen U, Morton LM, Mirabello L, Tucker MA, Tirode F, Chanock SJ, Delattre O.

Nat Commun. 2018 Aug 9;9(1):3184. doi: 10.1038/s41467-018-05537-2.

4.

Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Jan Pencik, Pham HTT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DNT, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2018 Jul 23;9(8):800. doi: 10.1038/s41419-018-0773-9.

5.

Ewing sarcoma.

Grünewald TGP, Cidre-Aranaz F, Surdez D, Tomazou EM, de Álava E, Kovar H, Sorensen PH, Delattre O, Dirksen U.

Nat Rev Dis Primers. 2018 Jul 5;4(1):5. doi: 10.1038/s41572-018-0003-x. Review.

PMID:
29977059
6.

Selective enhancer changes in osteosarcoma lung metastasis.

Kovar H.

Nat Med. 2018 Feb 7;24(2):126-127. doi: 10.1038/nm.4487. No abstract available.

PMID:
29414935
7.

Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts.

van der Lelij P, Lieb S, Jude J, Wutz G, Santos CP, Falkenberg K, Schlattl A, Ban J, Schwentner R, Hoffmann T, Kovar H, Real FX, Waldman T, Pearson MA, Kraut N, Peters JM, Zuber J, Petronczki M.

Elife. 2017 Jul 10;6. pii: e26980. doi: 10.7554/eLife.26980.

8.

EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.

Katschnig AM, Kauer MO, Schwentner R, Tomazou EM, Mutz CN, Linder M, Sibilia M, Alonso J, Aryee DNT, Kovar H.

Oncogene. 2017 Oct 26;36(43):5995-6005. doi: 10.1038/onc.2017.202. Epub 2017 Jul 3.

9.

EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.

Mutz CN, Schwentner R, Aryee DNT, Bouchard EDJ, Mejia EM, Hatch GM, Kauer MO, Katschnig AM, Ban J, Garten A, Alonso J, Banerji V, Kovar H.

Oncotarget. 2017 Apr 11;8(15):24679-24693. doi: 10.18632/oncotarget.14976.

10.

C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells.

Gardiner JD, Abegglen LM, Huang X, Carter BE, Schackmann EA, Stucki M, Paxton CN, Lor Randall R, Amatruda JF, Putnam AR, Kovar H, Lessnick SL, Schiffman JD.

Oncotarget. 2017 Apr 18;8(16):26013-26026. doi: 10.18632/oncotarget.14847.

11.

DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.

Sheffield NC, Pierron G, Klughammer J, Datlinger P, Schönegger A, Schuster M, Hadler J, Surdez D, Guillemot D, Lapouble E, Freneaux P, Champigneulle J, Bouvier R, Walder D, Ambros IM, Hutter C, Sorz E, Amaral AT, de Álava E, Schallmoser K, Strunk D, Rinner B, Liegl-Atzwanger B, Huppertz B, Leithner A, de Pinieux G, Terrier P, Laurence V, Michon J, Ladenstein R, Holter W, Windhager R, Dirksen U, Ambros PF, Delattre O, Kovar H, Bock C, Tomazou EM.

Nat Med. 2017 Mar;23(3):386-395. doi: 10.1038/nm.4273. Epub 2017 Jan 30.

12.

Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.

Radic-Sarikas B, Tsafou KP, Emdal KB, Papamarkou T, Huber KV, Mutz C, Toretsky JA, Bennett KL, Olsen JV, Brunak S, Kovar H, Superti-Furga G.

Mol Cancer Ther. 2017 Jan;16(1):88-101. doi: 10.1158/1535-7163.MCT-16-0235. Epub 2016 Nov 15.

13.

The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma.

Schwentner R, Herrero-Martin D, Kauer MO, Mutz CN, Katschnig AM, Sienski G, Alonso J, Aryee DN, Kovar H.

Oncotarget. 2017 Feb 14;8(7):10980-10993. doi: 10.18632/oncotarget.14091.

14.

High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.

He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K.

Gene. 2017 Jan 5;596:137-146. doi: 10.1016/j.gene.2016.10.021. Epub 2016 Oct 17.

PMID:
27760381
15.

Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Pencik J, Pham HT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DN, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2016 Oct 13;7(10):e2419. doi: 10.1038/cddis.2016.268. Erratum in: Cell Death Dis. 2018 Jul 23;9(8):800.

16.

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report.

Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JVMG, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GHS, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS.

Clin Sarcoma Res. 2016 Mar 16;6:3. doi: 10.1186/s13569-016-0043-5. eCollection 2016.

17.

Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome.

Ruiz-Pinto S, Pita G, Patiño-García A, García-Miguel P, Alonso J, Pérez-Martínez A, Sastre A, Gómez-Mariano G, Lissat A, Scotlandi K, Serra M, Ladenstein R, Lapouble E, Pierron G, Kontny U, Picci P, Kovar H, Delattre O, González-Neira A.

Ann Oncol. 2016 Sep;27(9):1788-93. doi: 10.1093/annonc/mdw234. Epub 2016 Jun 10.

PMID:
27287205
18.

EWS-FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway.

Mutz CN, Schwentner R, Kauer MO, Katschnig AM, Kromp F, Aryee DN, Erhardt S, Goiny M, Alonso J, Fuchs D, Kovar H.

FEBS Lett. 2016 Jul;590(14):2063-75. doi: 10.1002/1873-3468.12243. Epub 2016 Jun 21.

19.

Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.

Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, Hong SH, Çelik H, Tirode F, Tuckermann J, Toretsky JA, Kenner L, Kovar H, Lee S, Sweet-Cordero EA, Nakamura T, Moriggl R, Delattre O, Üren A.

Oncotarget. 2017 May 23;8(21):34141-34163. doi: 10.18632/oncotarget.9388.

20.

Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine.

Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, Zielinski C, Penninger JM, Kerjaschki D, Stingl G, Smolen JS, Valenta R, Lassmann H, Kovar H, Jäger U, Kornek G, Müller M, Sörgel F.

J Innate Immun. 2016;8(2):111-20. doi: 10.1159/000443526. Epub 2016 Feb 5.

21.

The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.

Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O.

Oncotarget. 2016 Feb 23;7(8):8613-24. doi: 10.18632/oncotarget.6937. Review.

22.

CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling.

Ventura S, Aryee DN, Felicetti F, De Feo A, Mancarella C, Manara MC, Picci P, Colombo MP, Kovar H, Carè A, Scotlandi K.

Oncogene. 2016 Jul 28;35(30):3944-54. doi: 10.1038/onc.2015.463. Epub 2015 Nov 30.

23.

YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.

Minas TZ, Han J, Javaheri T, Hong SH, Schlederer M, Saygideğer-Kont Y, Çelik H, Mueller KM, Temel I, Özdemirli M, Kovar H, Erkizan HV, Toretsky J, Kenner L, Moriggl R, Üren A.

Oncotarget. 2015 Nov 10;6(35):37678-94. doi: 10.18632/oncotarget.5520.

24.

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.

Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, Delattre O, Paulussen M, Picci P, Sundby Hall K, van den Berg H, Ladenstein R, Michon J, Hjorth L, Judson I, Luksch R, Bernstein ML, Marec-Bérard P, Brennan B, Craft AW, Womer RB, Juergens H, Oberlin O.

J Clin Oncol. 2015 Sep 20;33(27):3036-46. doi: 10.1200/JCO.2014.59.5256. Epub 2015 Aug 24. Review.

PMID:
26304893
25.

SLFN11: Achilles' Heel or Troublemaker.

Kovar H.

Clin Cancer Res. 2015 Sep 15;21(18):4033-4. doi: 10.1158/1078-0432.CCR-15-0883. Epub 2015 Jun 1.

26.

Development of curative therapies for Ewing sarcomas by interdisciplinary cooperative groups in Europe.

Bölling T, Braun-Munzinger G, Burdach S, Calaminus G, Craft A, Delattre O, Deley MC, Dirksen U, Dockhorn-Dworniczak B, Dunst J, Engel S, Faldum A, Fröhlich B, Gadner H, Göbel U, Gosheger G, Hardes J, Hawkins DS, Hjorth L, Hoffmann C, Kovar H, Kruseova J, Ladenstein R, Leuschner I, Lewis IJ, Oberlin O, Paulussen M, Potratz J, Ranft A, Rössig C, Rübe C, Sauer R, Schober O, Schuck A, Timmermann B, Tirode F, van den Berg H, van Valen F, Vieth V, Willich N, Winkelmann W, Whelan J, Womer RB.

Klin Padiatr. 2015 May;227(3):108-15. doi: 10.1055/s-0035-1545263. Epub 2015 May 18.

PMID:
25985445
27.

EWS-FLI1 employs an E2F switch to drive target gene expression.

Schwentner R, Papamarkou T, Kauer MO, Stathopoulos V, Yang F, Bilke S, Meltzer PS, Girolami M, Kovar H.

Nucleic Acids Res. 2015 Mar 11;43(5):2780-9. doi: 10.1093/nar/gkv123. Epub 2015 Feb 20.

28.

Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1.

Tomazou EM, Sheffield NC, Schmidl C, Schuster M, Schönegger A, Datlinger P, Kubicek S, Bock C, Kovar H.

Cell Rep. 2015 Feb 24;10(7):1082-95. doi: 10.1016/j.celrep.2015.01.042. Epub 2015 Feb 19.

29.

Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.

Svoboda LK, Harris A, Bailey NJ, Schwentner R, Tomazou E, von Levetzow C, Magnuson B, Ljungman M, Kovar H, Lawlor ER.

Epigenetics. 2014 Dec;9(12):1613-25. doi: 10.4161/15592294.2014.988048.

30.

Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma.

Ban J, Aryee DN, Fourtouna A, van der Ent W, Kauer M, Niedan S, Machado I, Rodriguez-Galindo C, Tirado OM, Schwentner R, Picci P, Flanagan AM, Berg V, Strauss SJ, Scotlandi K, Lawlor ER, Snaar-Jagalska E, Llombart-Bosch A, Kovar H.

Cancer Res. 2014 Nov 15;74(22):6578-88. doi: 10.1158/0008-5472.CAN-14-1736. Epub 2014 Oct 3.

31.

Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.

Kovar H.

Expert Opin Ther Targets. 2014 Nov;18(11):1315-28. doi: 10.1517/14728222.2014.947963. Epub 2014 Aug 27. Review.

PMID:
25162919
32.

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.

Aryee DN, Niedan S, Ban J, Schwentner R, Muehlbacher K, Kauer M, Kofler R, Kovar H.

Br J Cancer. 2013 Nov 12;109(10):2696-704. doi: 10.1038/bjc.2013.635. Epub 2013 Oct 15.

33.

Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.

Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, Pötschger U, Kontny U, Kovar H.

Oncogene. 2014 Jul 24;33(30):3927-38. doi: 10.1038/onc.2013.361. Epub 2013 Sep 2.

34.

Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer.

Bilke S, Schwentner R, Yang F, Kauer M, Jug G, Walker RL, Davis S, Zhu YJ, Pineda M, Meltzer PS, Kovar H.

Genome Res. 2013 Nov;23(11):1797-809. doi: 10.1101/gr.151340.112. Epub 2013 Aug 12.

35.

ESF-EMBO Symposium "Molecular Biology and Innovative Therapies in Sarcomas of Childhood and Adolescence" Sept 29-Oct 4, Polonia Castle Pultusk, Poland.

Schäfer BW, Koscielniak E, Kovar H, Fulda S.

Front Oncol. 2013 Jun 4;3:142. doi: 10.3389/fonc.2013.00142. eCollection 2013.

36.

Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells.

Hutter C, Kauer M, Simonitsch-Klupp I, Jug G, Schwentner R, Leitner J, Bock P, Steinberger P, Bauer W, Carlesso N, Minkov M, Gadner H, Stingl G, Kovar H, Kriehuber E.

Blood. 2012 Dec 20;120(26):5199-208. doi: 10.1182/blood-2012-02-410241. Epub 2012 Oct 16.

37.

The first European interdisciplinary ewing sarcoma research summit.

Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R.

Front Oncol. 2012 May 29;2:54. doi: 10.3389/fonc.2012.00054. eCollection 2012.

38.

Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.

Lehner M, Götz G, Proff J, Schaft N, Dörrie J, Full F, Ensser A, Muller YA, Cerwenka A, Abken H, Parolini O, Ambros PF, Kovar H, Holter W.

PLoS One. 2012;7(2):e31210. doi: 10.1371/journal.pone.0031210. Epub 2012 Feb 15.

39.

Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma.

Postel-Vinay S, Véron AS, Tirode F, Pierron G, Reynaud S, Kovar H, Oberlin O, Lapouble E, Ballet S, Lucchesi C, Kontny U, González-Neira A, Picci P, Alonso J, Patino-Garcia A, de Paillerets BB, Laud K, Dina C, Froguel P, Clavel-Chapelon F, Doz F, Michon J, Chanock SJ, Thomas G, Cox DG, Delattre O.

Nat Genet. 2012 Feb 12;44(3):323-7. doi: 10.1038/ng.1085.

PMID:
22327514
40.

Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.

Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H.

Hum Pathol. 2012 Aug;43(8):1300-7. doi: 10.1016/j.humpath.2011.10.010. Epub 2012 Jan 13.

PMID:
22245111
41.

Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma.

Bennani-Baiti IM, Aryee DN, Ban J, Machado I, Kauer M, Mühlbacher K, Amann G, Llombart-Bosch A, Kovar H.

J Pathol. 2011 Nov;225(3):353-63. doi: 10.1002/path.2966. Epub 2011 Aug 24.

PMID:
21984123
42.

Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology.

Thomas DM, Wilhelm M, Cleton-Jansen AM, Dirksen U, Entz-Werlé N, Gelderblom H, Hassan B, Jürgens H, Koster J, Kovar H, Lankester AC, Lewis IJ, Myklebost O, Nathrath MH, Picci P, Whelan JS, Hogendoorn PC, Bielack SS.

J Adolesc Young Adult Oncol. 2011 Sep;1(3):118-23. doi: 10.1089/jayao.2012.0005.

PMID:
26811922
43.

The molecular basis of sarcoma.

Lessnick SL, Kovar H, Houghton P.

Sarcoma. 2011;2011:864130. doi: 10.1155/2011/864130. Epub 2011 Jun 7. No abstract available.

44.

An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.

Winter GE, Rix U, Lissat A, Stukalov A, Müllner MK, Bennett KL, Colinge J, Nijman SM, Kubicek S, Kovar H, Kontny U, Superti-Furga G.

Mol Cancer Ther. 2011 Oct;10(10):1846-56. doi: 10.1158/1535-7163.MCT-11-0100. Epub 2011 Jul 18.

45.

Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.

Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN, Schaefer KL, Nakatani F, Scotlandi K, Reiter M, Strunk D, Speleman F, Vandesompele J, Kovar H.

Oncogene. 2011 May 5;30(18):2173-80. doi: 10.1038/onc.2010.581. Epub 2011 Jan 10.

46.

Dr. Jekyll and Mr. Hyde: The Two Faces of the FUS/EWS/TAF15 Protein Family.

Kovar H.

Sarcoma. 2011;2011:837474. doi: 10.1155/2011/837474. Epub 2010 Dec 9.

47.

Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma.

Bennani-Baiti IM, Cooper A, Lawlor ER, Kauer M, Ban J, Aryee DN, Kovar H.

Clin Cancer Res. 2010 Jul 15;16(14):3769-78. doi: 10.1158/1078-0432.CCR-10-0558. Epub 2010 Jun 4.

48.

AURKA inhibitors: right in time.

Kovar H.

Pediatr Blood Cancer. 2010 Jul 15;55(1):3-4. doi: 10.1002/pbc.22548. No abstract available.

PMID:
20486161
49.

Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.

Aryee DN, Niedan S, Kauer M, Schwentner R, Bennani-Baiti IM, Ban J, Muehlbacher K, Kreppel M, Walker RL, Meltzer P, Poremba C, Kofler R, Kovar H.

Cancer Res. 2010 May 15;70(10):4015-23. doi: 10.1158/0008-5472.CAN-09-4333. Epub 2010 May 4.

50.

CD133 expression in chemo-resistant Ewing sarcoma cells.

Jiang X, Gwye Y, Russell D, Cao C, Douglas D, Hung L, Kovar H, Triche TJ, Lawlor ER.

BMC Cancer. 2010 Mar 26;10:116. doi: 10.1186/1471-2407-10-116.

Supplemental Content

Support Center